AU2003206413A1 - Substituted amino carboxamides for the treatment of alzheimer's disease - Google Patents

Substituted amino carboxamides for the treatment of alzheimer's disease

Info

Publication number
AU2003206413A1
AU2003206413A1 AU2003206413A AU2003206413A AU2003206413A1 AU 2003206413 A1 AU2003206413 A1 AU 2003206413A1 AU 2003206413 A AU2003206413 A AU 2003206413A AU 2003206413 A AU2003206413 A AU 2003206413A AU 2003206413 A1 AU2003206413 A1 AU 2003206413A1
Authority
AU
Australia
Prior art keywords
alzheimer
disease
treatment
substituted amino
carboxamides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003206413A
Other languages
English (en)
Other versions
AU2003206413A8 (en
Inventor
Barbara Jagodzinska
Martha A. Warpehoski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Elan Pharmaceuticals LLC
Original Assignee
Pharmacia and Upjohn Co
Elan Pharmaceuticals LLC
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Elan Pharmaceuticals LLC, Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of AU2003206413A8 publication Critical patent/AU2003206413A8/xx
Publication of AU2003206413A1 publication Critical patent/AU2003206413A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003206413A 2002-01-04 2003-01-06 Substituted amino carboxamides for the treatment of alzheimer's disease Abandoned AU2003206413A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US34531602P 2002-01-04 2002-01-04
US60/345,316 2002-01-04
US35041902P 2002-01-18 2002-01-18
US60/350,419 2002-01-18
PCT/US2003/000326 WO2003057721A2 (en) 2002-01-04 2003-01-06 Substituted amino carboxamides for the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
AU2003206413A8 AU2003206413A8 (en) 2003-07-24
AU2003206413A1 true AU2003206413A1 (en) 2003-07-24

Family

ID=26994342

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003206413A Abandoned AU2003206413A1 (en) 2002-01-04 2003-01-06 Substituted amino carboxamides for the treatment of alzheimer's disease

Country Status (8)

Country Link
US (1) US6962934B2 (https=)
EP (1) EP1458745A2 (https=)
JP (1) JP2005534614A (https=)
AU (1) AU2003206413A1 (https=)
BR (1) BR0306724A (https=)
CA (1) CA2472617A1 (https=)
MX (1) MXPA04006575A (https=)
WO (1) WO2003057721A2 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045551B2 (en) * 2002-11-22 2006-05-16 Bristol-Myers Squibb Company 1-aryl-2-hydroxyethyl amides as potassium channel openers
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
JP2007516207A (ja) * 2003-06-30 2007-06-21 メルク　エンド　カムパニー　インコーポレーテッド アルツハイマー病の治療のためのＮ−アルキルフェニルカルボキサミドβ−セクレターゼ阻害剤
CA2543756A1 (en) * 2003-10-30 2005-05-12 Elan Pharmaceuticals, Inc. Hydroxypropyl amides for the treatment of alzheimer's disease
US7550481B2 (en) 2003-12-19 2009-06-23 Merck & Co., Inc. Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of Alzheimer's disease
WO2005070407A1 (en) * 2004-01-21 2005-08-04 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using aspartyl-protease inihibitors
CA2563639A1 (en) 2004-04-20 2005-11-03 Merck & Co., Inc. 2, 4, 6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
JP2007533743A (ja) 2004-04-20 2007-11-22 メルク　エンド　カムパニー　インコーポレーテッド アルツハイマー病治療のためのβ−セクレターゼ阻害薬として有用な１，３，５−置換フェニル誘導体化合物
WO2005113582A1 (en) * 2004-05-22 2005-12-01 Boehringer Ingelheim International Gmbh Substituted ethane-1,2-diamines for the treatment of alzheimer's disease
US7714021B2 (en) * 2004-06-15 2010-05-11 Merck & Co., Inc. Pyrrolidin-3-yl compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease
JP2008534541A (ja) * 2005-03-30 2008-08-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換１，２−エチレンジアミン、前記化合物を含む薬物、それらの使用及びそれらの製造方法
NZ562314A (en) 2005-04-08 2010-02-26 Comentis Inc Compounds which inhibit beta-secretase activity and methods of use thereof
EP1915339A1 (de) * 2005-08-11 2008-04-30 Boehringer Ingelheim International GmbH Inhibitoren der beta-sekretase zur behandlung der alzheimer- erkrankung
US20100168070A1 (en) * 2005-08-11 2010-07-01 Niklas Heine Compounds for the treatment of alzheimer's disease
US20100144681A1 (en) * 2005-08-11 2010-06-10 Klaus Fuchs Compounds for the treatment of alzheimer's disease
US20090042867A1 (en) * 2005-08-11 2009-02-12 Klaus Fuchs Compounds for the treatment of alzheimer's disease
US7872009B2 (en) 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
US7838676B2 (en) 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
WO2007061670A1 (en) 2005-11-21 2007-05-31 Amgen Inc. Beta-secretase modulators and methods of use
US7745484B2 (en) 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
WO2008147544A1 (en) 2007-05-25 2008-12-04 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
CL2008001500A1 (es) 2007-05-25 2008-12-26 Amgen Inc Compuestos derivados de hidroxietil amina sustituidas, moduladores de betasecretasa; proceso de preparacion de dichos c ompuestos; composicion farmaceutica que los comprende; y su uso para tratar un trastorno neurologico, tal como alzheimer, sindrome de down, demencia degenerativa, entre otros.
US8222264B2 (en) 2007-07-06 2012-07-17 Boehringer Ingelheim International Gmbh Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture
US7803809B2 (en) 2008-11-12 2010-09-28 Amgen Inc. Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use
MY148558A (en) * 2008-09-11 2013-04-30 Amgen Inc Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use
WO2011063233A1 (en) 2009-11-23 2011-05-26 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
EP2504330A1 (en) 2009-11-23 2012-10-03 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
CA2788363A1 (en) 2010-01-19 2011-07-28 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
EP2547685A1 (en) 2010-03-15 2013-01-23 Amgen Inc. Spiro-tetracyclic ring compounds as beta - secretase modulators
US8497264B2 (en) 2010-03-15 2013-07-30 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US9346827B2 (en) 2011-02-07 2016-05-24 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
WO2013044092A1 (en) 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
WO2014078314A1 (en) 2012-11-15 2014-05-22 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362912A (en) 1989-05-23 1994-11-08 Abbott Laboratories Process for the preparation of a substituted diaminodiol
US5539122A (en) 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
US5352705A (en) * 1992-06-26 1994-10-04 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
CA2170020C (en) 1992-12-29 2005-08-02 Dale J. Kempf Retroviral protease inhibiting compounds
JPH11507538A (ja) 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ
US6316440B1 (en) * 1998-07-30 2001-11-13 Warner-Lambert Company Reduced dipeptide analogues as calcium channel antagonists
JP2003502342A (ja) * 1999-06-15 2003-01-21 エラン ファーマスーティカルズ インコーポレイテッド ベータ−セクレターゼのスタチン誘導テトラペプチド阻害剤

Also Published As

Publication number Publication date
EP1458745A2 (en) 2004-09-22
US20030166580A1 (en) 2003-09-04
AU2003206413A8 (en) 2003-07-24
WO2003057721A3 (en) 2004-03-25
WO2003057721A2 (en) 2003-07-17
JP2005534614A (ja) 2005-11-17
BR0306724A (pt) 2006-04-11
MXPA04006575A (es) 2004-10-04
CA2472617A1 (en) 2003-07-17
US6962934B2 (en) 2005-11-08

Similar Documents

Publication Publication Date Title
AU2003206413A1 (en) Substituted amino carboxamides for the treatment of alzheimer's disease
EP1392287B8 (en) Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease
AU2003219690A1 (en) Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
AU2003220096A1 (en) Methods for alzheimer's disease treatment and cognitive enhancement
AU2002319615A1 (en) Methods for diagnosing and treating alzheimer's disease and parkinson's disease
AU2003273213A1 (en) Amyloid peptide inactivating enzyme to treat alzheimer's disease
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer's disease
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
AU2002312897A1 (en) Drugs for the treatment of the alzheimer disease
AU2002212471A1 (en) Peptides for use in the treatment of alzheimer's disease
AU2003303141A1 (en) Hydroxypropyl amides for the treatment of alzheimer's disease
AU2003254146A1 (en) Methods for the treatment of parkinson's disease
AU2003273310A1 (en) Substituted aminoethers for the treatment of alzheimer's disease
AU2003238046A1 (en) Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer's disease
AU2003284898A1 (en) Combinative nicotinic/d1 agonism therapy for the treatment of alzheimer's disease
AU2003303217A1 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
AU2003299101A1 (en) Compounds for the treatment of alzheimer's disease
AU2002303957A1 (en) Method of treating alzheimer's disease with se-containing peptide
AU2002357232A1 (en) Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease
AU2003236714A1 (en) Diagnosis of alzheimer's disease based on the habeta42:habeta40 ratio
AU2003286530A1 (en) Substituted peptides useful in the treatment of alzheimer's disease
AU2003230848A1 (en) Methods and compositions for treating alzheimer's disease
AU2003260745A1 (en) Sulphonylamino derivatives for the treatment of alzheimer's disease
AU2002320537A1 (en) Diaminediols for the treatment of alzheimer's disease
AU2002316622A1 (en) Aminediols for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase